On the HCPLive Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.
March 7th 2024
On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.
February 26th 2024
February 7th 2024
Earn CME Credits While Advancing Your Expertise in Internal Medicine
April 18-19, 2024
Register Now!
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Cases and Conversations™: Evidence-Based Approaches to Management of CKD in Your Patients with T2DM
September 25, 2024
Register Now!
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
Advances In™: The Potential Role of Ultra-Long-Acting Basal Insulin Therapies in Type 2 Diabetes
View More
6th Annual Advanced Practice Collaborative
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Cases and Conversations™: Guideline Recommendations for the Use of Basal Insulin Therapy in Type 2 Diabetes
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
Clinical Consultations™: Optimal Approaches to Recognizing and Treating ANCA-Associated Vasculitis
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Daily Soft Drink Consumption Increases Obesity, Overweight Rates in Adolescents
July 27th 2023A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.
Tirzepatide Further Cements Weight Loss Benefit in SURMOUNT-3 and SURMOUNT-4 Trials
July 27th 2023On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.
Liraglutide Could Improve Weight Loss after Poor Response to Metabolic Surgery
July 26th 2023The BARI-OPTIMISE randomized clinical trial reports individuals with poor weight loss after metabolic surgery had significantly greater reductions in body weight after treatment with 3.0 mg liraglutide, compared with placebo.
ASA Urges Withholding GLP-1 RA Therapy Prior to Elective Procedures
July 14th 2023With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.
Study Suggests Rising Obesity Prevalence May Have Altered Perceptions of Healthy Body Weights
July 6th 2023An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.
Retatrutide Showcases Historic Weight-Lowering, Glycemic Control Benefits in Phase 2 Data
June 27th 2023Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.
Increased Doses of Oral Semaglutide Can Induce Pronounced Weight Loss, Improve Glycemic Control
June 26th 2023Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.
Survodutide, Formerly BI 456906, Impresses in Phase 2 Dose-Finding Trial
June 23rd 2023Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.
10 Years of Obesity: A Decade of Advancement and Challenges
June 23rd 2023To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.
Study Links Weight Loss Surgery in Adolescents, Young Adults to Weakened Bones
June 13th 2023A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.
Metformin Could Reduce Long COVID Risk in People with Overweight or Obesity
June 9th 2023Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.
Analysis Predicts Obesity as Leading Risk Factor for Heart Attacks by 2050
June 8th 2023An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
Bariatric, Metabolic Procedures on the Rise in US Youth and Adolescents
May 30th 2023An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.
Metabolic Syndrome Could Worsen Damaging Effects of Alcohol Use on Liver
May 12th 2023Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.